Boehringer's Gilotrif Gets FDA Approval for NSCLC

Boehringer Ingelheim announces approval of its first oncology drug after regulators in the USA gave the green light to Gilotrif for late-stage non-small cell lung cancer. Read the full story

More News:

All news »

What are your comments?

You cannot post comments until you have logged in. Login Here.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments